Imatinib Qilu

Imatinib, the active ingredient in Imatinib Qilu, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific cancers by inhibiting abnormal cell signaling and is used in patients with chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor.

GNH USA supplies Imatinib Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, and clinical research institutions worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before distribution.

Imatinib is a targeted therapy that inhibits tyrosine kinase‑driven cancers.

- Chronic myeloid leukemia (CML): Reduces disease progression by blocking BCR‑ABL signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Improves remission rates through inhibition of BCR‑ABL. - Gastrointestinal stromal tumor (GIST): Controls tumor growth by targeting c‑KIT and PDGFR.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Edema: swelling, often in the extremities. - Fatigue: generalized tiredness. - Muscle cramps: involuntary muscle contractions. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: decreased left ventricular ejection fraction. - Severe neutropenia: markedly low white blood cell count. - Thrombocytopenia: reduced platelet levels. - Pulmonary hypertension: increased pressure in lung arteries. - Anaphylaxis: severe allergic reaction.

When prescribing Imatinib, clinicians should consider several safety precautions to minimize risk.

- Pregnancy: Category D; use only if benefits outweigh risks. - Liver function: Monitor hepatic enzymes regularly. - Cardiac function: Assess baseline ejection fraction and monitor for decline. - Hematologic parameters: Check blood counts frequently for neutropenia or thrombocytopenia. - Drug interactions: Review concomitant medications for major interaction potential. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Imatinib interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): can raise Imatinib plasma levels. - CYP3A4 strong inducers (e.g., rifampin, carbamazepine): can reduce Imatinib exposure.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may decrease absorption. - Concomitant anticoagulants (e.g., warfarin): increased bleeding risk. - CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism. - Vaccines (live attenuated): reduced efficacy.